Tamer Othman, MD
Hematology · Irvine, CANPI 1316471980
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 10 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 9 manufacturers reported payments, led by AbbVie at 28.1% of the total. 2025 is the largest year on record at $228, more than ten times the $21 reported in 2020. That places this record below the midpoint for hematology clinicians in CA, where the typical reported total is $4,615.
Across 10 payments — averaging $51.49 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$145
- Bristol Myers Squibb$125
- Janssen Scientific Affairs, LLC$73
- Autolus Inc$67
- Takeda Pharmaceuticals U.S.A., Inc.$24
- Daiichi Sankyo Inc.$23
- plus $58 from 3 others
What the payments were for
- Food & beverage$515100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 2 | $145 |
| Bristol Myers Squibb | 1 | $125 |
| Janssen Scientific Affairs, LLC | 1 | $73 |
| Autolus Inc | 1 | $67 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $24 |
| Daiichi Sankyo Inc. | 1 | $23 |
| Ipsen Biopharmaceuticals, Inc | 1 | $21 |
| AstraZeneca | 1 | $21 |
| Novartis | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$515 in reported general payments places this provider in the 30th percentile of 178 hematology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JakafiRuxolitinib Phosphate | 12 | $220,861 |
| Acyclovir | 11 | $123 |
Paid to pharmacies, not to this prescriber.
Other hematology in Irvine
- Krisstina GowinIrvine$66K
- Everett MeyerStanford$2.1M
- Doris QuonLos Angeles$1.5M
- Amrita KrishnanDuarte$671K
- Ilene WeitzLos Angeles$631K
- Vinod PullarkatDuarte$576K
- Hope RugoSan Francisco$537K
- Alexey DanilovDuarte$407K
- Caroline PiatekLos Angeles$391K
- Deepu MadduriStanford$348K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.